The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cabozantinib in Hepatocellular and Renal Cell Carcinoma: Multikinase Inhibition

Targeted oral therapy for advanced HCC after sorafenib failure and metastatic RCC across multiple lines of treatment

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Cabozantinib in Hepatocellular and Renal Cell Carcinoma: Multikinase Inhibition?

Cabozantinib is an oral small-molecule multikinase inhibitor blocking MET, VEGFR1-3, AXL, RET and KIT among other receptor tyrosine kinases.

MET pathway inhibition is particularly relevant given MET upregulation as escape mechanism in tumors progressing on VEGFR-targeted therapy.

FDA approval includes advanced hepatocellular carcinoma after sorafenib failure based on CELESTIAL trial showing improved overall survival.

Renal cell carcinoma indications span first-line setting in combination with nivolumab and subsequent lines as monotherapy after VEGFR therapy.

Differentiated thyroid cancer that is radioiodine refractory represents another approved indication based on multikinase activity.

Symptoms

Hand-foot skin reaction with palmoplantar erythema, blistering and pain affects up to half of patients requiring dose modification and supportive care.
Hypertension typically develops within first weeks of treatment requiring antihypertensive initiation or intensification with calcium channel blockers preferred.
Diarrhea is common and may be severe requiring loperamide, hydration and dose interruption with management algorithms guiding intervention.
Fatigue, weight loss and decreased appetite affect quality of life and may require dose reduction and nutritional support.
Hepatotoxicity with transaminase elevation requires baseline and serial liver function monitoring with dose adjustments per established criteria.

Risk Factors

Pre-existing hypertension increases cardiovascular risk during cabozantinib therapy requiring optimized blood pressure control before initiation.
Prior abdominal radiation, recent surgery or active inflammatory bowel disease increase perforation and fistula risk requiring careful patient selection.
Concurrent anticoagulation with warfarin requires careful INR monitoring given drug interactions and bleeding risk on multikinase inhibitor.
Hepatic impairment requires dose modification with Child-Pugh class B requiring 40 mg starting dose instead of 60 mg.
Strong CYP3A4 inducers and inhibitors require dose adjustments given metabolic pathway involvement.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe hypertension above 160/100 mmHg or hypertensive crisis requires immediate evaluation and antihypertensive intervention.
  • Severe diarrhea with dehydration, electrolyte abnormalities or persistent grade 3 symptoms warrants prompt medical attention.
  • Severe hand-foot skin reaction with functional limitation requires dermatology consultation and dose modification consideration.
  • Abdominal pain, severe nausea or signs of bowel perforation including peritoneal signs require emergency surgical evaluation.
  • Significant transaminase elevation, jaundice or liver dysfunction requires hepatology consultation and treatment interruption.

Treatment Methods

01
Initiation typically at 60 mg daily for RCC monotherapy or 40 mg daily in combination with nivolumab with empty stomach administration.
02
Hand-foot skin reaction management includes urea-based emollients, mechanical pressure avoidance and dose reduction in severe cases.
03
Hypertension management with proactive antihypertensive therapy and regular monitoring with calcium channel blockers and ARB combinations.
04
Diarrhea management with loperamide, dietary modification and dose interruption with severe cases requiring hospitalization.
05
Comprehensive monitoring including blood pressure, liver function, hand-foot examination and quality of life assessment supports optimal therapy continuation while managing the multifaceted toxicity profile of this important targeted agent.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.